Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib Topical Gel Extension Study in Gorlin Syndrome
NCT04308395Phase 3Terminated
- Sponsor
- Sol-Gel Technologies
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of patidegib in nevoid basal cell carcinoma syndrome (NBCCS), sponsored by Sol-Gel Technologies. Primary endpoint: Incidence of Treatment-emergent Adverse Events at 12 months. Started Jun 2020; status: terminated.
02
Drugs
patidegib
03
Conditions
nevoid basal cell carcinoma syndrome (NBCCS)
Beyond the preview
Go deeper on NCT04308395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308395.